BRIEF—Gastric cancer indication for Ono's Opdivo in Taiwan

The Taiwanese subsidiary of Japan’s Ono Pharmaceutical has won approval for an extension to the label for Opdivo (nivolumab) to treat advanced or recurrent gastric cancer patients in the second-line setting.

It’s estimated that there are about 3,800 patients diagnosed with gastric cancer annually, resulting in about 2,350 deaths per year in Taiwan.

Ono is working with its long-time Opdivo collaborator Bristol-Myers Squibb to develop and commercialize the drug in Japan, South Korea and Taiwan, under the terms of a 2014 agreement.